Figure 5 | Oncogene

Figure 5

From: Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer

Figure 5

Comparison of stemness-related features driven by d16HER2 and WTHER2 in engineered human BC cells. (a) First mammosphere generation by MCF7-Mock, MCF7_d16 and MCF7_WT and of (b) T47D-Mock, T47D_d16 and T47D_WT evaluated as MFE (%). The results are the mean±s.d. (n=6). Significance was calculated by a two-tailed paired t-test. (c) Representative plots and (d) summary of the data showing the % of ALDH-positive cells in the HER2-positive cell subset of MCF7_d16 and MCF7_WT cells and in bulk MCF7-Mock cells. The results are the mean±s.d. (n=3). (e) Representative plots and (f) summary showing the % of ALDH-positive cells in the HER2-positive cell subset of T47D_d16 and T47D_WT cells and T47D-Mock cells. The results are the mean±s.d. (n=3). Significance was calculated by a two-tailed unpaired t-test. The basal expression of HER2 in MCF7-Mock and T47D-Mock cells was established as the threshold to identify d16 and WT-positive cellular subsets in the bulk MCF7_d16, MCF7_WT, T47D-d16 and T47D-WT engineered cell lines.

Back to article page